Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
07:00am, Wednesday, 05'th Jun 2024
The stock market continues making new highs seemingly almost every week. Investors are thrilled about new developments in fields such as semiconductors and artificial intelligence that could lead to t
7 Dividend Stocks to Invest In for a Lifetime of Income
06:40am, Wednesday, 05'th Jun 2024
Finding good dividend stocks to buy amid market turbulence is essential in today's investing environment to maximize profits and minimize risks. These seven dividend stocks to buy have performance ind
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
02:00am, Wednesday, 05'th Jun 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing AS
3 Dividend Stocks That Even Ken Griffin Is Buying
06:15am, Tuesday, 04'th Jun 2024
Hedge fund operator Ken Griffin is the founder and CEO of Citadel, one of the world's most successful alternative investment firms. It has over $103 billion in assets under management (AUM) and Griffi
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
03:01pm, Monday, 03'rd Jun 2024
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell ther
Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
09:00am, Monday, 03'rd Jun 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabta
SECAUCUS, N.J.--(BUSINESS WIRE)-- #AI--ZT Systems, a leading provider of accelerated computing solutions for artificial intelligence (AI) and cloud, today announced its ACX200 platform featuring the N
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 stud
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
02:06pm, Friday, 31'st May 2024
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Gilead's Trodelvy extends lung cancer survival by just 1.3 months in trial
08:09am, Friday, 31'st May 2024
Gilead Sciences' Trodelvy improved survival by 1.3 months more than chemotherapy in previously treated patients with advanced lung cancer in a late-stage trial, a difference that was not statistically
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
08:07am, Friday, 31'st May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA
Gilead's Trodelvy fails to meet main goal in late-stage study
05:04pm, Thursday, 30'th May 2024
Gilead Sciences said on Thursday its drug Trodelvy, tested in patients with bladder cancer who previously received chemotherapy, did not meet the main goal of a late-stage study.
Gilead Provides Update on Phase 3 TROPiCS-04 Study
04:45pm, Thursday, 30'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial c
